Considering the physiological role of CTLA-4, the blockade of this molecule in the context of a tumor immunotherapy would be important to directly enhance the functional properties of effector T cells as well as for inhibiting Treg cell-mediated immunosuppression of effector T cells. The gene discussed is CTLA4; the disease is neoplasm.